USA flag logo/image

An Official Website of the United States Government

Biomarker for Early Detection of Chronic Kidney Disease

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96083
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
DK089892
Solicitation Year:
N/A
Solicitation Topic Code:
NIDDK
Solicitation Number:
N/A
Small Business Information
SEQUELA
6508 Old Floydsburg Road Pewee Valley, KY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Biomarker for Early Detection of Chronic Kidney Disease
Agency: HHS
Contract: 1R43DK089892-01
Award Amount: $592,427.00
 

Abstract:

DESCRIPTION (provided by applicant): This proposal is submitted in response to the program announcement PA-09-080, Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) and intende d to be directed to the NIDDK, with a potential dual assignment to the NHLBI. There are an estimated 14 million Americans with early chronic kidney disease (CKD). Early diagnosis and treatment of CKD are the only cost-effective means to reverse this growin g problem. Current methods and biomarkers that are used to assess CKD are effective once the disease is well established, but none, thus far, are reliable for the detection of early renal disease. Existing tests used by physicians today are all essentially markers of kidney filtration function. NIH recognizes the challenge to diagnose CKD early during its initiation and development phases in order to prevent further renal damage, reduce cardiovascular risk, and minimize the economic impact of CKD through pr ogram announcements such as PA-09-204 (Development and Validation of Disease Biomarkers) and PA-09-181 (Non-Invasive Methods for Diagnosis and Progression of Diabetes, Kidney, Urological, Hematological and Digestive Diseases). We will produce a new ELISA f or CKD based upon the use of a novel biomarker that reflects, in part, the pathophysiology of kidney disease. Detection of this biomarker for CKD will give laboratory results and clinical insight that is complementary to creatinine-based GFR estimates (eGF R) as well as tests for urine albumin. Development of this test should result in a more reliable identification and detection of early CKD patients. In addition, our CKD ELISA would give physicians the ability to evaluate patients that have been recently d iagnosed with hypertension or diabetes, the two leading causes of CKD. In turn, this Phase I proposal will evaluate the prototype assay in both populations. We will look for the influence of comorbid conditions and medications on assay performance. Lastly, we will evaluate whether patient characteristics such as age, gender, BMI, ethnicity, and other factors impact on assay performance. The information gained from this test will also lead to a better basic understanding of the biological mechanisms underlyi ng CKD. Sequela requests Phase I support so that we can evaluate a prototype assay and test its feasibility to help identify at-risk patients for early kidney disease and monitor therapy with the ultimate goal of obtaining FDA approval. PUBLIC HEALT H RELEVANCE: Chronic Kidney Disease affects nearly 26 million people in the United States, which places them at higher risk of renal failure and hemodialysis. We will develop an ELISA to aid in the diagnosis of early kidney disease to aid physicians in ear lier treatment and better assessment of chronic kidney disease.

Principal Investigator:

Stephen L. Carrithers
5024327712
SEQUELASTEVE@YAHOO.COM

Business Contact:

Richard T. Coughlin
SequelaRick@yahoo.com
Small Business Information at Submission:

SEQUELA
SEQUELA 92 WOODLANDS DR FALMOUTH, ME -

EIN/Tax ID: 190019417
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No